Article PDF
Avoid common mistakes on your manuscript.
References
Hilbe W. Changing paradigms in clinical trials. memo, 3: 1–2, 2010
Dittrich C. Pharmacoeconomy in cancer therapy. memo, 3: 99–102, 2010
O'Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol, 28(Suppl. 15): 115S, 2010
Bartsch R, Ziebermayr R. Metastatic breast cancer – ASCO 2010. memo, 3: 159–162, 2010
Scheithauer W. Colorectal cancer – ASCO 2010. memo, 3: 155–156, 2010
Wöll E. Gastric cancer – ASCO 2010. memo, 3: 168–170, 2010
Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Hohenberger P, Jensen K, Kieser M, Slanger TE. GE Adenocarcinoma Meta-analysis Group: Meta-analysis of preoperative chemotherapy (CTX) versus primary surgery for locoregionally advanced adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus (GE adenocarcinoma). J Clin Oncol, 28: 15s, 2010 (suppl; abstr 4022)
Kang Y, Ohtsu A, Van Cutsem E, Rha SY, Sawaki A, Park S, Lim H, Wu J, Langer B, Shah MA. AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first – line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol, 28: 18s, 2010 (suppl; abstr LBA4007)
Bang Y, Kwak EL, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol, 28: 18s, 2010 (suppl, abstr 3)
Pall G. Lung cancer – ASCO 2010. memo, 3: 172–176, 2010
Temel JS, Greer J, et al. Effect of palliative care (PC) on quality of life (QoL), aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC patients: results of a phase III randomized trial. J Clin Oncol, 28: 15s, 2010 (suppl; abstr 7509)
Lee S, Rudd R, et al. TOPICAL: Randomised phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy. J Clin Oncol, 28: 15s, 2010 (suppl; abstr 7504)
Marosi M, Preusser M. Neurooncology – ASCO 2010. memo, 3: 157–158, 2010
O'Day S, Hodi FS, McDermott DF, et al. A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol, 28: 18s, 2010 (suppl; abstr 4)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hilbe, W. Oncology in 2010 – small steps towards personalized medicine with special focus on elderly cancer patients. memo 3, 153–154 (2010). https://doi.org/10.1007/s12254-010-0235-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-010-0235-2